FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378072329> ?p ?o ?g. }

• W4378072329 abstract "Because of the short half-life of non-vitamin K antagonist oral anticoagulants (NOACs), consistent drug adherence is crucial to maintain the effect of anticoagulants for stroke prevention in atrial fibrillation (AF). Considering the low adherence to NOACs in practice, we developed a mobile health platform that provides an alert for drug intake, visual confirmation of drug administration, and a list of medication intake history. This study aims to evaluate whether this smartphone app-based intervention will increase drug adherence compared with usual care in patients with AF requiring NOACs in a large population.This prospective, randomized, open-label, multicenter trial (RIVOX-AF study) will include a total of 1,042 patients (521 patients in the intervention group and 521 patients in the control group) from 13 tertiary hospitals in South Korea. Patients with AF aged ≥19 years with one or more comorbidities, including heart failure, myocardial infarction, stable angina, hypertension, or diabetes mellitus, will be included in this study. Participants will be randomly assigned to either the intervention group (MEDI-app) or the conventional treatment group in a 1:1 ratio using a web-based randomization service. The intervention group will use a smartphone app that includes an alarm for drug intake, visual confirmation of drug administration through a camera check, and presentation of a list of medication intake history. The primary endpoint is adherence to rivaroxaban by pill count measurements at 12 and 24 weeks. The key secondary endpoints are clinical composite endpoints, including systemic embolic events, stroke, major bleeding requiring transfusion or hospitalization, or death during the 24 weeks of follow-up.This randomized controlled trial will investigate the feasibility and efficacy of smartphone apps and mobile health platforms in improving adherence to NOACs.The study design has been registered in ClinicalTrial.gov (NCT05557123)." @default.
• W4378072329 created "2023-05-25" @default.
• W4378072329 creator A5003862414 @default.
• W4378072329 creator A5006512871 @default.
• W4378072329 creator A5007429638 @default.
• W4378072329 creator A5017419314 @default.
• W4378072329 creator A5024314666 @default.
• W4378072329 creator A5029710464 @default.
• W4378072329 creator A5037144708 @default.
• W4378072329 creator A5070651548 @default.
• W4378072329 creator A5071177828 @default.
• W4378072329 creator A5072059904 @default.
• W4378072329 creator A5085434738 @default.
• W4378072329 creator A5091510154 @default.
• W4378072329 date "2023-05-24" @default.
• W4378072329 modified "2023-09-28" @default.
• W4378072329 title "The ReInforcement of adherence via self-monitoring app orchestrating biosignals and medication of RivaroXaban in patients with atrial fibrillation and co-morbidities: a study protocol for a randomized controlled trial (RIVOX-AF)" @default.
• W4378072329 cites W1972110417 @default.
• W4378072329 cites W2006382463 @default.
• W4378072329 cites W2035228137 @default.
• W4378072329 cites W2096246254 @default.
• W4378072329 cites W2097854437 @default.
• W4378072329 cites W2136489990 @default.
• W4378072329 cites W2152623033 @default.
• W4378072329 cites W2162508946 @default.
• W4378072329 cites W2162586165 @default.
• W4378072329 cites W2272515352 @default.
• W4378072329 cites W2281540926 @default.
• W4378072329 cites W2395936517 @default.
• W4378072329 cites W2397026500 @default.
• W4378072329 cites W2508495213 @default.
• W4378072329 cites W2563665632 @default.
• W4378072329 cites W2576091398 @default.
• W4378072329 cites W2588800208 @default.
• W4378072329 cites W2604186734 @default.
• W4378072329 cites W2738405916 @default.
• W4378072329 cites W2750662095 @default.
• W4378072329 cites W2775094040 @default.
• W4378072329 cites W2780840915 @default.
• W4378072329 cites W2799395920 @default.
• W4378072329 cites W2799837895 @default.
• W4378072329 cites W2799839997 @default.
• W4378072329 cites W2899247532 @default.
• W4378072329 cites W2914635881 @default.
• W4378072329 cites W2957544571 @default.
• W4378072329 cites W2972747751 @default.
• W4378072329 cites W2979575337 @default.
• W4378072329 cites W2981072889 @default.
• W4378072329 cites W2982355856 @default.
• W4378072329 cites W3003343618 @default.
• W4378072329 cites W3038756868 @default.
• W4378072329 cites W3082188176 @default.
• W4378072329 cites W3134794500 @default.
• W4378072329 cites W4225082354 @default.
• W4378072329 cites W4226367249 @default.
• W4378072329 doi "https://doi.org/10.3389/fcvm.2023.1130216" @default.
• W4378072329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37324622" @default.
• W4378072329 hasPublicationYear "2023" @default.
• W4378072329 type Work @default.
• W4378072329 citedByCount "0" @default.
• W4378072329 crossrefType "journal-article" @default.
• W4378072329 hasAuthorship W4378072329A5003862414 @default.
• W4378072329 hasAuthorship W4378072329A5006512871 @default.
• W4378072329 hasAuthorship W4378072329A5007429638 @default.
• W4378072329 hasAuthorship W4378072329A5017419314 @default.
• W4378072329 hasAuthorship W4378072329A5024314666 @default.
• W4378072329 hasAuthorship W4378072329A5029710464 @default.
• W4378072329 hasAuthorship W4378072329A5037144708 @default.
• W4378072329 hasAuthorship W4378072329A5070651548 @default.
• W4378072329 hasAuthorship W4378072329A5071177828 @default.
• W4378072329 hasAuthorship W4378072329A5072059904 @default.
• W4378072329 hasAuthorship W4378072329A5085434738 @default.
• W4378072329 hasAuthorship W4378072329A5091510154 @default.
• W4378072329 hasBestOaLocation W43780723291 @default.
• W4378072329 hasConcept C126322002 @default.
• W4378072329 hasConcept C127413603 @default.
• W4378072329 hasConcept C168563851 @default.
• W4378072329 hasConcept C1862650 @default.
• W4378072329 hasConcept C203092338 @default.
• W4378072329 hasConcept C2776301958 @default.
• W4378072329 hasConcept C2776704044 @default.
• W4378072329 hasConcept C2778661090 @default.
• W4378072329 hasConcept C2779161974 @default.
• W4378072329 hasConcept C2780645631 @default.
• W4378072329 hasConcept C2908647359 @default.
• W4378072329 hasConcept C71924100 @default.
• W4378072329 hasConcept C78519656 @default.
• W4378072329 hasConcept C99454951 @default.
• W4378072329 hasConceptScore W4378072329C126322002 @default.
• W4378072329 hasConceptScore W4378072329C127413603 @default.
• W4378072329 hasConceptScore W4378072329C168563851 @default.
• W4378072329 hasConceptScore W4378072329C1862650 @default.
• W4378072329 hasConceptScore W4378072329C203092338 @default.
• W4378072329 hasConceptScore W4378072329C2776301958 @default.
• W4378072329 hasConceptScore W4378072329C2776704044 @default.
• W4378072329 hasConceptScore W4378072329C2778661090 @default.
• W4378072329 hasConceptScore W4378072329C2779161974 @default.
• W4378072329 hasConceptScore W4378072329C2780645631 @default.
• W4378072329 hasConceptScore W4378072329C2908647359 @default.
• W4378072329 hasConceptScore W4378072329C71924100 @default.

• next